Lynx1 Capital Management LP
20 insider transactions on file
All transactions
| Date | Ticker | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-25 | PASG | Passage BIO, Inc. | Buy | 50,055 | $4.12 | $206,101.46 | filing |
| 2026-03-31 | KRRO | Korro Bio, Inc. | Buy | 520 | $10.60 | $5,512.00 | filing |
| 2025-12-23 | TCRX | TScan Therapeutics, Inc. | Buy | 6,232 | $0.90 | $5,601.94 | filing |
| 2025-12-22 | TCRX | TScan Therapeutics, Inc. | Buy | 75,500 | $0.90 | $67,950.00 | filing |
| 2025-12-19 | TCRX | TScan Therapeutics, Inc. | Buy | 80,069 | $0.90 | $71,974.02 | filing |
| 2025-10-28 | CGEM | Cullinan Therapeutics, Inc. | Buy | 165,667 | $8.40 | $1.4M | filing |
| 2025-10-21 | NEUP | Neuphoria Therapeutics Inc. | Buy | 639,110 | $5.14 | $3.3M | filing |
| 2025-10-17 | CGEM | Cullinan Therapeutics, Inc. | Buy | 32,217 | $7.84 | $252,565.17 | filing |
| 2025-10-16 | CGEM | Cullinan Therapeutics, Inc. | Buy | 150,000 | $8.86 | $1.3M | filing |
| 2025-10-15 | CGEM | Cullinan Therapeutics, Inc. | Buy | 51,500 | $7.94 | $409,049.05 | filing |
| 2025-10-14 | CGEM | Cullinan Therapeutics, Inc. | Buy | 15,032 | $7.59 | $114,047.78 | filing |
| 2025-10-10 | CGEM | Cullinan Therapeutics, Inc. | Buy | 277,298 | $7.36 | $2.0M | filing |
| 2025-10-09 | CGEM | Cullinan Therapeutics, Inc. | Buy | 626,043 | $6.70 | $4.2M | filing |
| 2025-10-08 | CGEM | Cullinan Therapeutics, Inc. | Buy | 556,300 | $6.46 | $3.6M | filing |
| 2025-09-15 | PASG | Passage BIO, Inc. | Buy | 11,900 | $6.99 | $83,175.05 | filing |
| 2025-09-12 | PASG | Passage BIO, Inc. | Buy | 19,783 | $6.99 | $138,299.00 | filing |
| 2025-09-11 | PASG | Passage BIO, Inc. | Buy | 325 | $6.96 | $2,260.64 | filing |
| 2025-07-24 | PASG | Passage BIO, Inc. | Buy | 66,423 | $5.71 | $379,454.67 | filing |
| 2025-07-23 | PASG | Passage BIO, Inc. | Buy | 49,302 | $5.74 | $283,032.92 | filing |
| 2025-07-22 | PASG | Passage BIO, Inc. | Buy | 13,123 | $5.44 | $71,337.94 | filing |
Insider transactions from SEC Form 4 filings via EDGAR. Names appear as filed and aren't normalized across issuers.